Dimerix Ltd (ASX: DXB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Dimerix Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $206.40 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 557.83 million
Earnings per share -0.038
Dividend per share N/A
Year To Date Return 63.41%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Dimerix Ltd (ASX: DXB)
    Latest News

    Two colleagues at work looking at a tablet and smiling at a rising share price.
    Share Gainers

    Why Dimerix, Paladin Energy, Pilbara Minerals, and Resolute Mining shares are storming higher today

    These shares are catching the eye with strong gains on Thursday. But why?

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why Dimerix, Life360, S2 Resources, and SG Fleet shares are sinking today

    These shares are missing out on the good times today. But why?

    Read more »

    A young boy in a business suit lifts his glasses above his eyes and gives a big wide mouthed smile to the camera with a stock market board in the background.
    Share Market News

    Top 10 most traded ASX shares and US stocks in June

    The most traded stock was an ASX 200 iron ore giant. But were investors buying or selling it?

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why Dimerix, New Hope, Pro Medicus, and West African Resources shares are sinking today

    These shares are having a tough time on Thursday. But why?

    Read more »

    Woman looks amazed and shocked as she looks at her laptop.
    Share Gainers

    If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

    The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Healthcare Shares

    2 ASX biotech shares that could be the next Telix Pharmaceuticals

    These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

    Read more »

    four excited doctors with their hands in the air
    Healthcare Shares

    Guess which ASX healthcare stock is rocketing 20% today

    This stock is rising despite raising capital. What's going on?

    Read more »

    a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
    Share Gainers

    Why Dimerix, Evolution, GQG, and Steadfast shares are climbing today

    These ASX shares are ending the week on a high.

    Read more »

    A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
    Healthcare Shares

    This ASX healthcare share has jumped 280% in just two days!

    Shareholders of this healthcare stock will be smiling long into the weekend.

    Read more »

    Rocket powering up and symbolising a rising share price.
    Healthcare Shares

    Guess which ASX healthcare share is rocketing 130% on some big news

    Some big news is getting investors excited on Thursday.

    Read more »

    Two lab technicians wearing white coats discuss results they see on a computer screen.
    Healthcare Shares

    Dimerix (ASX:DXB) share price jumps on COVID study update

    The biopharma specialist is bringing its study to Australia.

    Read more »

    A health worker wearing disposable gloves holds a vial, treating a patient.
    Healthcare Shares

    Dimerix (ASX:DXB) share price soars as boss looks back on 'pivotal' year

    It was a big FY21 for Dimerix. Here's what its CEO has to say about it.

    Read more »

    DXB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Dimerix Ltd

    A clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix's lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200

    DXB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Dec 2024 $0.37 $0.01 2.74% 2,355,839 $0.37 $0.38 $0.36
    03 Dec 2024 $0.37 $0.03 8.96% 2,252,343 $0.34 $0.37 $0.34
    02 Dec 2024 $0.34 $-0.02 -5.71% 877,312 $0.36 $0.36 $0.34
    29 Nov 2024 $0.35 $0.00 0.00% 758,430 $0.36 $0.36 $0.35
    28 Nov 2024 $0.35 $0.02 5.97% 1,297,358 $0.34 $0.36 $0.34
    27 Nov 2024 $0.34 $0.02 6.25% 680,949 $0.33 $0.34 $0.33
    26 Nov 2024 $0.32 $-0.01 -3.03% 723,998 $0.33 $0.34 $0.32
    25 Nov 2024 $0.33 $-0.02 -5.80% 1,049,798 $0.34 $0.35 $0.33
    22 Nov 2024 $0.35 $0.02 6.15% 1,104,501 $0.33 $0.35 $0.33
    21 Nov 2024 $0.33 $-0.01 -2.99% 1,443,730 $0.34 $0.34 $0.30
    20 Nov 2024 $0.34 $-0.01 -2.90% 2,893,592 $0.35 $0.37 $0.33
    19 Nov 2024 $0.35 $-0.02 -5.56% 2,345,655 $0.36 $0.37 $0.35
    18 Nov 2024 $0.36 $-0.02 -5.33% 1,248,141 $0.37 $0.38 $0.36
    15 Nov 2024 $0.38 $0.00 0.00% 1,548,033 $0.38 $0.39 $0.37
    14 Nov 2024 $0.38 $-0.02 -5.13% 2,057,685 $0.39 $0.39 $0.37
    13 Nov 2024 $0.39 $0.00 0.00% 716,915 $0.39 $0.39 $0.38
    12 Nov 2024 $0.39 $0.00 0.00% 1,151,070 $0.39 $0.40 $0.38
    11 Nov 2024 $0.39 $-0.02 -4.94% 797,631 $0.41 $0.41 $0.39
    08 Nov 2024 $0.41 $0.03 8.00% 1,624,946 $0.37 $0.41 $0.37
    07 Nov 2024 $0.38 $-0.01 -2.60% 1,820,717 $0.39 $0.39 $0.37
    06 Nov 2024 $0.39 $0.01 2.63% 709,301 $0.39 $0.39 $0.39
    05 Nov 2024 $0.38 $-0.01 -2.60% 615,803 $0.39 $0.40 $0.38

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    21 Oct 2024 Mark Diamond Issued 300,000 $110,148
    Employee Share Ownership Plan. Black-Scholes valuation
    21 Oct 2024 Hugh Alsop Issued 300,000 $110,148
    Employee Share Ownership Plan. Black-Scholes valuation
    21 Oct 2024 Nina Webster Issued 1,500,000 $550,740
    Employee Share Ownership Plan. Black-Scholes valuation
    21 Oct 2024 Sonia Poli Issued 300,000 $110,148
    Employee Share Ownership Plan. Black-Scholes valuation, as per announcement on 25-10-2024
    21 Oct 2024 Clinton Snow Issued 300,000 $110,148
    Employee Share Ownership Plan. Black-Scholes valuation
    30 Jul 2024 Hugh Alsop Expiry 167,202 $72,732
    Options expired.
    25 Jul 2024 Sonia Poli Exercise 167,202 $66,880
    Exercise of options.
    25 Jul 2024 Sonia Poli Buy 167,202 $66,880
    Exercise of options.
    10 Apr 2024 Sonia Poli Expiry 37,500 $11,437
    Options expired. As per announcement on 03-06-2024
    10 Apr 2024 Nina Webster Expiry 25,000 $7,625
    Options expired.
    27 Mar 2024 Nina Webster Buy 33,000 $10,230
    On-market trade.
    26 Mar 2024 Sonia Poli Exercise 12,501 $1,575
    Exercise of options.
    26 Mar 2024 Sonia Poli Issued 12,501 $1,575
    Exercise of options.
    19 Mar 2024 Nina Webster Exercise 93,750 $11,812
    Exercise of options.
    19 Mar 2024 Nina Webster Issued 93,750 $11,812
    Exercise of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Mark P Diamond Non-Executive Director Dec 2023
    Mr Diamond is a senior pharmaceutical executive with more than thirty years within the pharmaceutical and biotechnology industries. Prior to his time at Antisense, Mark served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations. Mark is currently a Senior Advisor for Boston based Global Investment Bank, Locust Walk and Biotech Advisor for Spark Plus, a Corporate Advisory specialist firm in Singapore.
    Mr Hugh Alsop Non-Executive Director May 2017
    Mr Alsop is an executive with experience in international business development, partnering, drug development and leadership of scientific teams. Hugh is currently CEO of Kinoxis Therapeutics, a private company developing novel therapeutics for substance use disorders and other neurological conditions. Prior to Kinoxis, Hugh was CEO of venture-backed private company Hatchtech, where he was responsible for several drug development programs for the international markets. Hugh is also a non-Executive director of private companies Servatus Ltd, Eflare Corporation Pty Ltd, Avalyn Australia Pty Ltd, AnaptysBio Pty Ltd and Lassen Therapeutics1 Pty Ltd.
    Ms Nina Webster Chief Executive OfficerManaging Director Aug 2018
    Ms Webster has experience in the pharmaceutical industry, with leadership roles across strategy, commercialization, intellectual property, scientific and operational aspects of product development. Nina worked in large Pharma, Wyeth Pharmaceuticals (UK). Nina is also a Non-Executive Director of Linear Clinical Research Limited and SYNthesis BioVentures Pty Ltd.
    Dr Sonia Maria Poli Non-Executive Director Jul 2015
    Dr Poli is a R&D professional with 20 years international experience in large and small pharmaceutical companies. Sonia is currently serving as advisor for several late-stage drug development projects approaching market authorization. Sonia was formerly Executive Manager at AC Immune,Nasdaq listed company, and Chief Scientific Officer at Minoryx and Addex Therapeutics and she has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche.
    Mr Clinton Snow Non-Executive Director May 2023
    Mr Snow has 20 years of experience as a technology leader with a focus in engineering management, project delivery, risk management and assurance. Clinton is providing advisory services to a family office with multiple Australian biotech investments.
    Mr Hamish George Chief Financial OfficerCompany Secretary May 2019
    -
    Robert Shepherd Chief Commercialization Officer
    -
    Hamish George Chief Financial OfficerCompany Secretary
    -
    David Fuller Chief Medical Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr Peter Fletcher Meurs 35,572,412 6.46%
    Skiptan Pty Ltd <P&M Meurs Family A/C> 29,732,028 5.40%
    J P Morgan Nominees Australia Pty Limited 17,807,381 3.23%
    HSBC Custody Nominees (Australia) Limited 11,098,120 2.02%
    Precision Opportunities Fund Ltd <Investment A/C> 10,080,875 1.83%
    Citicorp Nominees Pty Limited 9,836,824 1.79%
    National Nominees Limited 8,197,234 1.49%
    Bavaria Bay Pty Ltd 7,316,992 1.33%
    BNP Paribas Noms Pty Ltd 6,041,838 1.10%
    Skiptan Pty Ltd <P&M Meurs Family A/C> i 5,928,514 1.08%
    Mr Richard Stanley De Ravin 5,485,000 1.00%
    Yodambao Pty Ltd <Yodambao Investment A/C> 5,480,732 1.00%
    Mrs Melinda Jane Coates & Mr Andrew Joseph Coates <Melindajcoates Superfund A/C> 5,450,000 0.99%
    Mrs Julie Maree Scott 4,500,000 0.82%
    Mr Philip Robert Scott 4,500,000 0.82%
    Mr Peter Fletcher Meurs i 4,446,552 0.84%
    Mr Andrew Joseph Coates & Mrs Melinda Jane Coates <Aj & Mj Coates S/F A/C> 4,306,000 0.78%
    Mr Zhaoyang Bi & Mrs Feifei Cheng <Bi&Cheng Superfund A/C> 3,800,000 0.69%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 3,317,351 1.09%
    Mrs Gwen Murray Pfleger <Pfleger Family A/C> 3,158,982 0.57%

    Profile

    since

    Note